Opinion
Video
Pathophysiology and Standard of Care in Generalized Myasthenia Gravis
Author(s):
Key Takeaways
- MG involves antibodies targeting acetylcholine receptors, disrupting neuromuscular transmission and causing muscle weakness.
- New therapeutic targets include MuSK and LRP4, offering potential for novel treatment strategies.
Panelists discuss how the current understanding of myasthenia gravis pathophysiology is informing the development of targeted treatments, alongside reviewing the standard of care for generalized myasthenia gravis (gMG).
Video content above is prompted by the following:
- What is our current understanding of the underlying pathophysiology of MG? How is this being utilized to design targeted agents to treat gMG?
- What is the standard of care for gMG?
Related Videos
Related Content
